FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085080236> ?p ?o ?g. }

• W2085080236 endingPage "S165" @default.
• W2085080236 startingPage "S164" @default.
• W2085080236 abstract "ASRM states that PGD may reduce the risk for conceiving a child with a genetic abnormality carried by one or both parents. BRCA 1/2 carriers are at considerable lifetime risk for developing breast and ovarian cancer as well as increase risk for colon, pancreatic and prostate cancer. BRCA 1/2 carriers are advised to undergo intensive cancer screening and undergo prophylactic oopherectomy once completed their family planning. To review the safety and outcome of our 29 IVF-PGD cycles in BRCA carriers. Retrospective study. Academic medical center. 19 BRCA carriers seen for counseling, of which, 13 patients initiated 29 IVF-PGD cycles between 1/07-4/12. IVF-ICSI-PGD. Pregnancy rate and IVF-PGD cycle outcome. We identified 19 BRCA carriers who were evaluated for infertility and counseled in the past 5 years. 6 patients chose other fertility treatment not including PGD. 13 couples underwent at least 1 IVF-PGD cycle(2.23 cycles/patient). The cohort included 6 female patients and 7 patients with male affected partners who were diagnosed with BRCA 1 (84%) or 2 (16%). 21 cycles (72%) resulted in a transfer of a biopsied unaffected day-5 embryos(average of 1.86 embryos/transfer). Total of 12 cycles resulted in positive pregnancy (41% per started cycle, 57% per transferred cycle) with 11 clinical pregnancies (4 set of twins). 3 pregnancies resulted in spontaneous abortion and 2 in voluntary termination of pregnancies following(SMA and MZ twins) and 7 had a live birth (53%). Our study suggests that PGD is an appropriate and safe option for BRCA 1 and 2 carriers and their partners who wish to conceive and have an unaffected offspring. This treatment is particularly appropriate for those undergoing IVF for infertility. Future studies pertaining to offering of routine IVF-PGD to BRCA 1/2 patients should be conducted, taking into account the patients’ physical and emotional condition, potential risk as well as ethical, socio-economic and medico-legal aspects.Tabled 1CharacteristicsBRCA 1/2IVF patients13IVF Cycles29Age31.81 ± 3.51BMI22.82 + 4.2Partners’ age34.95 ± 7.44BRCA 1 : BRCA211 : 2Affected- Partner : Patient6 : 7Peak E22220.84 ± 1094.32Total Gonadotropins2037.83 ± 655.30Days of Stimulation9.26 ± 3.08 Open table in a new tab" @default.
• W2085080236 created "2016-06-24" @default.
• W2085080236 creator A5004737499 @default.
• W2085080236 creator A5007325379 @default.
• W2085080236 creator A5027684035 @default.
• W2085080236 creator A5030119818 @default.
• W2085080236 creator A5036569875 @default.
• W2085080236 creator A5045098501 @default.
• W2085080236 creator A5055525271 @default.
• W2085080236 creator A5077016924 @default.
• W2085080236 creator A5084558291 @default.
• W2085080236 date "2012-11-01" @default.
• W2085080236 modified "2023-09-27" @default.
• W2085080236 title "BRCA 1/2 Carriers and IVF-ICSI-PGD Cycles – What To Expect When You Are Cycling?" @default.
• W2085080236 doi "https://doi.org/10.1016/j.jmig.2012.08.452" @default.
• W2085080236 hasPublicationYear "2012" @default.
• W2085080236 type Work @default.
• W2085080236 sameAs 2085080236 @default.
• W2085080236 citedByCount "0" @default.
• W2085080236 crossrefType "journal-article" @default.
• W2085080236 hasAuthorship W2085080236A5004737499 @default.
• W2085080236 hasAuthorship W2085080236A5007325379 @default.
• W2085080236 hasAuthorship W2085080236A5027684035 @default.
• W2085080236 hasAuthorship W2085080236A5030119818 @default.
• W2085080236 hasAuthorship W2085080236A5036569875 @default.
• W2085080236 hasAuthorship W2085080236A5045098501 @default.
• W2085080236 hasAuthorship W2085080236A5055525271 @default.
• W2085080236 hasAuthorship W2085080236A5077016924 @default.
• W2085080236 hasAuthorship W2085080236A5084558291 @default.
• W2085080236 hasBestOaLocation W20850802361 @default.
• W2085080236 hasConcept C131872663 @default.
• W2085080236 hasConcept C2777688143 @default.
• W2085080236 hasConcept C2778279030 @default.
• W2085080236 hasConcept C2778642596 @default.
• W2085080236 hasConcept C2779234561 @default.
• W2085080236 hasConcept C29456083 @default.
• W2085080236 hasConcept C54355233 @default.
• W2085080236 hasConcept C71924100 @default.
• W2085080236 hasConcept C86803240 @default.
• W2085080236 hasConceptScore W2085080236C131872663 @default.
• W2085080236 hasConceptScore W2085080236C2777688143 @default.
• W2085080236 hasConceptScore W2085080236C2778279030 @default.
• W2085080236 hasConceptScore W2085080236C2778642596 @default.
• W2085080236 hasConceptScore W2085080236C2779234561 @default.
• W2085080236 hasConceptScore W2085080236C29456083 @default.
• W2085080236 hasConceptScore W2085080236C54355233 @default.
• W2085080236 hasConceptScore W2085080236C71924100 @default.
• W2085080236 hasConceptScore W2085080236C86803240 @default.
• W2085080236 hasIssue "6" @default.
• W2085080236 hasLocation W20850802361 @default.
• W2085080236 hasOpenAccess W2085080236 @default.
• W2085080236 hasPrimaryLocation W20850802361 @default.
• W2085080236 hasRelatedWork W2017194889 @default.
• W2085080236 hasRelatedWork W2046842812 @default.
• W2085080236 hasRelatedWork W2074469795 @default.
• W2085080236 hasRelatedWork W2113485405 @default.
• W2085080236 hasRelatedWork W2189483303 @default.
• W2085080236 hasRelatedWork W2401739700 @default.
• W2085080236 hasRelatedWork W2404744075 @default.
• W2085080236 hasRelatedWork W2425622575 @default.
• W2085080236 hasRelatedWork W4302337340 @default.
• W2085080236 hasRelatedWork W2612005728 @default.
• W2085080236 hasVolume "19" @default.
• W2085080236 isParatext "false" @default.
• W2085080236 isRetracted "false" @default.
• W2085080236 magId "2085080236" @default.
• W2085080236 workType "article" @default.